BridgeBio Pharma is a commercial-stage biopharmaceutical company focused on discovering, developing, and delivering medicines for patients with genetic diseases. It operates a decentralized hub-and-spoke model and has received FDA approval for three products: Attruby (acoramidis) for ATTR-CM, Nulibry (fosdenopterin) for MoCD Type A, and Truseltiq (infigratinib) for cholangiocarcinoma (withdrawn). Attruby generated $362.4 million in U.S. net product revenues in 2025. The company also has multiple Phase 3 programs in achondroplasia, LGMD2I/R9, and ADH1.
expected 2026-11-09
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-24 | 2025-12-31 | 0001743881-26-000009 | EDGAR | 152K words |
| 2025-02-20 | 2024-12-31 | 0000950170-25-024119 | EDGAR | 159K words |
| 2024-02-22 | 2023-12-31 | 0000950170-24-018811 | EDGAR | 147K words |
| 2023-02-23 | 2022-12-31 | 0000950170-23-004145 | EDGAR | 149K words |
| 2022-02-25 | 2021-12-31 | 0000950170-22-002030 | EDGAR | — |
| 2021-02-25 | 2020-12-31 | 0001564590-21-008969 | EDGAR | — |
| 2020-03-03 | 2019-12-31 | 0001564590-20-008260 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-10 | 2026-06-30 | 0001743881-26-000027 | EDGAR | 97K words |
| 2025-10-29 | 2025-09-30 | 0001743881-25-000012 | EDGAR | 50K words |
| 2025-08-05 | 2025-06-30 | 0000950170-25-103192 | EDGAR | 55K words |
| 2025-04-29 | 2025-03-31 | 0000950170-25-060314 | EDGAR | 48K words |
| 2024-11-12 | 2024-09-30 | 0000950170-24-124577 | EDGAR | 57K words |
| 2024-08-01 | 2024-06-30 | 0000950170-24-089326 | EDGAR | 51K words |
| 2024-05-02 | 2024-03-31 | 0000950170-24-052165 | EDGAR | 44K words |
| 2023-11-02 | 2023-09-30 | 0000950170-23-058255 | EDGAR | 48K words |
| 2023-08-03 | 2023-06-30 | 0000950170-23-037977 | EDGAR | 47K words |
| 2023-05-04 | 2023-03-31 | 0000950170-23-017812 | EDGAR | 42K words |
| 2022-11-03 | 2022-09-30 | 0000950170-22-021936 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0000950170-22-014824 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-31 | 0001140361-26-035055 | EDGAR | 1K words |
| 2026-08-17 | 0001140361-26-033282 | EDGAR | 1K words |
| 2026-08-10 | 0001743881-26-000026 | EDGAR | 7K words |
| 2026-07-22 | 0001140361-26-029291 | EDGAR | 2K words |
| 2026-03-30 | 0001140361-26-011991 | EDGAR | 1K words |
| 2026-02-24 | 0001743881-26-000008 | EDGAR | 7K words |
| 2026-02-12 | 0001140361-26-004995 | EDGAR | 2K words |
| 2026-01-21 | 0001140361-26-001843 | EDGAR | 2K words |
| 2026-01-12 | 0001140361-26-000971 | EDGAR | 6K words |
| 2025-10-29 | 0001140361-25-039705 | EDGAR | 2K words |
143 total filings indexed. 114 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001743881 |
| Ticker | BBIO |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.bridgebio.com |
| Listed | 2019-06-27 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/BBIO (~200 tokens, structured JSON with cryptographic provenance)